All In MedTech

Device Trial Radar · NCT05042154

Prevalence of OSA in COPD and the Clinical Impact of OSA Diagnosis and Treatment

Last checked: Nov 19, 2026Latest source record: Sep 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 31, 2021

Primary completion

Oct 31, 2022

Study completion Jan 1, 2023

Sponsor

Lead sponsor
Atlantic Health SystemAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 13, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

COPD is a major cause of morbidity and mortality and is characterized by breathing impairment and related symptoms. Obstructive sleep apnea (OSA) is a highly prevalent condition that adversely affects breathing during sleep. The co-occurrence of OSA and COPD in an individual has been referred to as the overlap syndrome (OVS). Regardless of whether OVS represents a single unique entity or two separate conditions in the same patient, the combined respiratory derangements of OSA and COPD are felt to be synergistic. Patients with COPD and OSA may have more frequent and severe nocturnal arterial hypoxemia and hypercapnia than in patients with OSA alone, as well as increased pulmonary hypertension and dysrhythmias. The reported prevalence of OSA in COPD varies widely depending on patient setting, COPD severity, diagnostic methodology, etc., ranging from 10 to 75%. The presence of OSA in patients with COPD has also been implicated as a risk factor for COPD exacerbations and associated hospitalizations. The coexistence of OSA and COPD is associated with increased risk of COPD exacerbation and shorter time to first exacerbation following diagnosis. 20% of patients discharged following an exacerbation of COPD are readmitted within 30 days, usually for respiratory-related problems. A randomized controlled trial on Gagnon 3 at Morristown Medical Center will be conducted to diagnose OSA in patients admitted with AECOPD. The WatchPAT One device will be used and can detect the presence of OSA. If OSA is diagnosed, the patient will then be offered and prescribed a home CPAP for use after hospital discharge. We will investigate 30-day of AECOPD readmission rates.

Conditions

  • Prevalence of OSA in Patients Hospitalized With COPD Exacerbation

Interventions

  • WatchPATDevice

    The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-Day Hospitals Readmissions for COPDTime frame: 30 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.